Drug Trial Radar · NCT07467993
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
Last checked: Nov 20, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
142
Planned (sponsor's estimate)
Start
Mar 16, 2026
Primary completion
Jul 29, 2027
Study completion Jul 29, 2027
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Mar 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy, safety, and tolerability of GXV813 in the treatment of an acute episode of schizophrenia
Conditions
- Schizophrenia
Interventions
GXV813Drug
GXV813 administered orally.
PlaceboDrug
Placebo administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Positive and Negative Symptom Scale (PANSS) total scoreTime frame: Baseline, Week 6
Locations
16 sites in 2 countries. Site status is shown where the registry gives one.
Pillar Clinical Research LLC
Bentonville, Arkansas · Recruiting
CNRI Los Angeles LLC
Pico Rivera, California · Recruiting
Segal Institute for Clinical Research
Miami, Florida · Recruiting
CenExel iResearch
Decatur, Georgia · Recruiting
Uptown Research Institute LLC
Chicago, Illinois · Recruiting
Pillar Clinical Research LLC
Chicago, Illinois · Recruiting
Arch Clinical Trials LLC
St Louis, Missouri · Recruiting
Novartis Investigative Site
Haskovo, Bulgaria · Recruiting
Novartis Investigative Site
Kazanlak, Bulgaria · Recruiting
Novartis Investigative Site
Lovech, Bulgaria · Recruiting
Novartis Investigative Site
Plovdiv, Bulgaria · Recruiting
Novartis Investigative Site
Sliven, Bulgaria · Recruiting
Novartis Investigative Site
Sofia, Bulgaria · Recruiting
Novartis Investigative Site
Veliko Tarnovo, Bulgaria · Recruiting
Novartis Investigative Site
Vratsa, Bulgaria · Recruiting
Novartis Investigative Site
Sofia, BGR, Bulgaria · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.